Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20582201 | 0.80 | ALDH1A1 (0.38) | KDM4EMAPTTHRBALDH1A1LMNA | |
| SCHEMBL20582183 | 0.76 | NOS2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20729355 | 0.76 | KCNQ4 (0.38) | KDM4EALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL20582107 | 0.72 | HTT (0.57) | KDM4EMAPTTHRBALDH1A1LMNA | |
| SCHEMBL29141804 | 0.69 | MAPT (0.59) | MAPTKMT2AMEN1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL3854786 | 0.68 | MAPT (0.43) | MAPTKMT2AMEN1SLC6A2SLC6A4 | |
| SCHEMBL29141769 | 0.67 | MAPT (0.42) | MAPTLMNAKMT2AMEN1GAA | |
| SCHEMBL29177417 | 0.66 | MEN1 (0.50) | KDM4EMAPTALDH1A1LMNAKMT2A | |
| SCHEMBL3856445 | 0.65 | NOS2 (0.45) | KDM4EMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL9510254 | 0.65 | MAPT (0.40) | KDM4EMAPTKMT2AMEN1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894414-B1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | NEUMORA THERAPEUTICS INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230093235-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2023-03-23 | — | — | US | disclosed |
| US-20230084719-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3634963-B1 | 1-(2-AZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS FOR TREATING NEUROPSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11186577-B2 | Vasopressin receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3894414-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | Blackthorn Therapeutics, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123872-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-3634963-A1 | 1-(2-AZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS FOR TREATING NEUROPSYCHOLOGICAL DISORDERS | Blackthorn Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190048013-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-02-14 | — | — | US | disclosed |
| WO-2018226769-A1 | 1-(2-AZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS FOR TREATING NEUROPSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186577-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | KDM4E 4273/4885MAPT 2563/4885THRB 116/4885 |
| US-20190048013-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1B, AVPR1A, AVPR2 | KDM4E 4273/4885MAPT 2563/4885THRB 116/4885 |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | KDM4E 4273/4885MAPT 2563/4885THRB 116/4885 |
| US-20230093235-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1B, AVPR1A, AVPR2 | KDM4E 4273/4885MAPT 2563/4885THRB 116/4885 |
| US-20230084719-A1 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | AVPR1B, AVPR1A, AVPR2 | KDM4E 2206/4885MAPT 1809/4885THRB 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.